Oxford BioMedica PLC Receives Notice Of Patent Allowance Extending Trovax® Protection In The United States

Oxford BioMedica (LSE: OXB), a gene therapy company, announced today that the US Patent and Trademark Office has issued a Notice of Allowance for a key patent application (USSN 09/533,798), which significantly extends the protection of TroVax, the Company’s lead cancer vaccine. It is expected that the patent will be issued during 2006. This patent is one of several granted and pending patents that protect the Company’s use of the 5T4 tumour antigen. The Notice of Allowance covers immunotherapy approaches directed against the 5T4 tumour antigen.

MORE ON THIS TOPIC